Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus postoperative adjuvant chemotherapy in resected pancreatic ductal adenocarcinoma
ChiCTR2300077535Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of envafolimab in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Disease-free survival and Treatment safety. Started Nov 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300077535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077535.